

VarIZIG™

VARICELLA ZOSTER IMMUNE GLOBULIN (HUMAN)*



Safety

- Solvent Detergent step validated to inactivate lipid enveloped viruses such as HIV, Hepatitis B and Hepatitis C¹
- Second viral inactivation step using a 35 nanometer filter validated to remove non-lipid enveloped viruses such as Hepatitis A and B19 Parvovirus¹

The strict precautions taken in the manufacture of VarIZIG™ dramatically reduce the potential for viral transmission.

Purity

- no mercurial preservatives¹
- low in contaminating IgA¹

Convenience

- Because of its high level of purity, VarIZIG™ can be administered intravenously or intramuscularly.¹



The advantages of immune globulin I.V. administration

	<u>I.V.</u>	<u>I.M.</u>
Peak titre ¹	40 ng/mL	20 ng/mL
Time to achieve peak titre ¹	<3 hours	5-10 days
Proteolysis/Loss of IgG extravascularly ^{2, 3}	no	yes
Limitation of volume administered ⁴	no	yes

* Schedule D Drug

¹ Product Monograph, VarIZIG™, Cangene Corporation. January 18, 2001.

² Bowman, J. M.: The advantages of Intravenous Rh-Immune Globulin. Clinical Obstetrics & Gynecology, Vol. 25, No. 2, June 1982; pp 341-347.

³ Berkman, S. A. et al.: Clinical Uses of Intravenous Immunoglobulins. Seminars in Hematology, Vol. 25, No. 2 (April), 1988; pp 140-158.

⁴ Pirofsky, B. et al: Individual patient variations in the kinetics of intravenous immune globulin administration. J Clin Immunol 2:7-14S, 1982.

CANGENE